Dataset from A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Ranging, Parallel-Group Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Volunteers

The primary objectives are to identify the highest safe and well-tolerated dose and frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV).

本研究的首要目标为：针对健康受试者（healthy volunteers，HV），探索在63至188微克的剂量范围内，以每两周或每四周的给药频次皮下注射（subcutaneous，SC）BIIB017（聚乙二醇化β-1a干扰素，PEGylated Interferon Beta-1a）时的最高安全耐受剂量与给药频次。